Value-based health insurance designs (VBIDs) are one approach to increase adherence to highly effective medications and simultaneously contain rising health care costs. The objective of this systematic review was to identify VBID effects on adherence and incentive designs within these programs that were associated with higher effects. Eight economic and medical databases were searched for literature. Random effects meta-analyses and mixed effects meta-regressions were used to synthesize VBID effects on adherence. Thirteen references with evaluation studies, including 12 patient populations with 79 outcomes, were used for primary meta-analyses. For qualitative review and sensitivity analyses, up to 19 references including 20 populations with 119 outcomes were used. Evidence of synthesized effects was good, because references with high risk of bias were excluded. VBIDs significantly increased adherence in all indication areas. Highest effects were found in medications indicated in heart diseases (4.05%-points, p < 0.0001). Each additional year increased effects by 0.15%-points (p < 0.01). VBIDs with education were more effective than without education, but the difference was not significant. Effects of VBIDs with full coverage were more than twice as high as effects of VBID without that option (4.52 vs 1.81%-points, p < 0.05). These findings were robust in most sensitivity analyses. It is concluded that VBID implementation should be encouraged, especially for patients with heart diseases, and that full coverage was associated with higher effects. This review may provide insight for policy-makers into how to make VBIDs more effective.
Introduction
Costs of pharmaceutical products account for a large share of rising health care costs in many European and other high income countries [1] . As a result, private health insurers and social health insurance systems have increased cost sharing for prescription medications to decrease unnecessary health care utilization [2, 3] . However, concerns have been raised that the utilization of clinically important, high-value medications is decreased as well. The financial burden of cost sharing could be problematic, especially for the sick and the poor [4, 5] . In 2016, about 33% of surveyed respondents in the United States (US) and about 7-18% of respondents in selected European and other high income countries faced financial barriers to health care [6] . Because cost sharing is usually based on costs and not on clinical value, patients may prefer less effective medications with lower cost over indicated but expensive, high-value medications. Non-adherence to high-value medications is problematic because it is considered to be associated with worse health and, therefore, increased health care costs [7] .
In 2001, Fendrick et al. [8] proposed a benefit-based copay to simultaneously contain cost and increase adherence. They proposed a benefit-based copay that is based on the clinical value of medications, not on costs. Health insurance designs that use benefit-based copays are called value-based health insurance designs (VBIDs) [9] . According to the original idea, apart from decreased cost sharing for high-value medications, VBID may also include increased cost sharing for low-value medications. However, to date, most VBIDs only reduced cost sharing for high-value medications [10] .
Because of promising results from the first experimental implementations of VBIDs, the number of health plans that offer VBIDs to patients with chronic diseases is increasing. For example, in France and the United Kingdom, some longterm diseases are exempt from cost sharing [2] . In Germany, patients with chronic diseases usually do not have to pay more than 1% of their income and, in the US, the Patient Protection and Affordable Care Act requires health plans to fully cover certain preventive services [2, 11] . To increase patients' understanding of the importance of high-value medications, VBIDs are often implemented in combination with education programs, such as educational material, nurse counseling, or more complex disease management programs (DMPs).
Previous systematic reviews found that lower cost sharing was able to increase the number of adherent patients without increasing total health care spending [12] [13] [14] . Many VBID evaluation studies have reported effects on adherence of patients with different chronic diseases and after different lengths of follow-up. Sometimes, the effects were also stratified to different medication classes [15] [16] [17] . To date, the evidence related to these outcomes has not been comprehensively synthesized. A comprehensive synthesis would provide better insight not only into whether VBIDs are effective, but where they are most effective and if VBID effects evolve over time.
To identify characteristics of effective VBIDs, VBIDs with different incentive designs need to be compared in a systematic and comprehensive way. In a previous systematic review it was found that lower cost sharing was associated with higher adherence [12] . However, it was not analyzed whether this finding was statistically significant. An empiric evaluation study of multiple VBIDs found that VBIDs that were more generous, did not include a DMP and were offered to high risk patients were associated with higher adherence [18] . However, because these analyses were based on VBIDs from a single pharmacy benefit manager and not on a systematic review, the generalizability of these findings is limited. A recent systematic review and meta-analyses found that the risk of non-adherence decreased with full coverage [19] . However, it is unclear whether this decline was significant. Furthermore, this study synthesized the outcomes of non-interventional studies, and it seems as though multiple outcomes from a single population were included without consideration of correlation between these outcomes [19, 20] . Therefore, to the knowledge of the author, there is no reliable evidence from meta-analyses about the VBID effect on adherence.
To answer the question how to make VBIDs more effective, a systematic review with meta-analyses was chosen. Specifically, the objective was to identify the VBID effect on adherence and incentive designs within these programs that were associated with higher effects. To follow that objective, first, the overall effect on adherence and the VBID time trend effect were analyzed. Second, differences of effects between different medication classes and indication areas were analyzed by meta-regressions. In subgroup analyses it was further evaluated whether VBIDs that were combined with educational interventions were associated with higher effects than VBIDs without education.
Methods

Systematic search and selection process
A systematic literature review was done in accordance with the Cochrane Collaboration recommendations [21] . Eight databases comprising medical, economic, health behavioral, and interdisciplinary research were searched on May 16, 2018: PsycINFO, Medline, EconLit, and Business Source Complete via EBSCOhost; Cochrane Library; ClinicalTrials.gov; Scopus; Web of Science Core Collection. Inclusion criteria were:
1. Empiric interventional evaluation studies of health plans with reduced cost sharing for medications prescribed for chronic diseases (heart diseases, diabetes, hyperlipidemia, hypertension, COPD, asthma). Cost sharing must be a percentage of costs or a fixed copay. Caps were excluded because they do not affect patients with low utilization. 2. No study with negative cost sharing was included. Negative cost sharing means that patients received a net gain from filling prescriptions, for example because cost sharing was overcompensated by payments for prescription fills [22] . 3. Included comparisons are:
• VBID vs usual medication coverage (VBID vs U) • VBID + education vs usual medication coverage (VBID + E vs U) • VBID + education vs usual medication coverage + education (VBID + E vs U + E) 4. Adherence must be measured as the percentage of days with prescribed daily dose available (e.g., as proportion of days covered or medication possession ratio). In nonrandomized studies, effects on adherence must be given as before-after values in treatment and control groups or measured by a difference in difference (DiD) or interrupted time series framework. 5. Quantitative synthesis of reported outcomes with inverse variance method must be possible [23] . Therefore, standard errors of VBID effects on adherence must be reported or possible to calculate. 6. For inclusion into primary meta-analyses: only references without high risk of bias.
VBID is usually defined as any health insurance design that aims to increase adherence to high-value medications by monetary incentives [8, 9] . However, the analyses in the present review were restricted to reduced cost-sharing designs because empiric evidence about increased cost sharing for low-value medications was found to be scarce [2, 24] . To ensure that reduced cost sharing was associated with clinical value, only VBIDs for medications prescribed for specified chronic diseases were included. Programs with negative cost sharing were excluded because, according to prospect theory, incentives exerted by gains and losses may not be comparable [25] . Furthermore, only one study was identified that used a negative cost-sharing intervention, which would make a subgroup-analysis of negative cost-sharing unfeasible [22] . In order to be able to identify causal VBID effects on adherence, either randomized controlled trials (RCTs) or non-randomized studies that enable a DiD framework were included [26] . To ensure high quality of synthesized evidence, studies with high risk of bias determined by risk of bias assessment were excluded from meta-analyses, but included in qualitative overviews and sensitivity analyses.
The search strategy was built from terms and synonyms for specified chronic diseases and related medications, cost sharing, health plans or prospective and retrospective study designs, and for adherence. The search strategy is presented in Online Appendix A. It was adjusted slightly for different databases. Given the inclusion criteria and search strategy, the author and a research assistant independently selected relevant literature. Discrepancies were solved by discussion.
Data extraction
Basic characteristics of each VBID evaluation, such as its name, the length of follow-up, and the index year, were extracted from the literature. The index year is the year of VBID implementation. Effects were collected on the level of patient populations because synthesis was also done on population level, not on level of references.
A combination of the name of the VBID evaluation study, and possibly the subgroup and the index year, was used for each distinct population as a population identifier (ID) (e.g., "CHORD 2 ambulatory clinics, 2005"). If the evaluation study or VBID did not have a name, the name of the insurance group or initiator of the program was taken, e.g., "A large employer".
Because VBIDs were often combined with educational interventions, which are also designed to increase adherence, education effects might bias VBID effects. Education effects were identified if VBIDs were combined with an existing education (E old ) or simultaneously implemented with a new education program (E new ). Because of the DiD framework, independent education effects of VBID + E new vs U + E new , VBID + E old vs U + E old , or VBID + E old vs U comparisons are cancelled out (Online Appendix B). However, VBID-education interaction effects or time trend effects of education might exist anyway. No education effects were identified in VBID vs U comparisons.
VBID incentive designs were analyzed in detail: a VBID was defined to include full coverage if either full coverage was provided for at least one tier or for all medications. It was also assessed whether education was individualized or standardized. Individualized education was defined as education that included at least individualized information or complex disease management, such as nurse counseling. Education was classified as standardized if the same information was provided to each patient, for example by informational letters, workbooks, or movies.
For quantitative synthesis, VBID effects on adherence percentage-points (%-points) and statistics that are required for meta-analysis were extracted from the literature. If multiple references were published on the same VBID program, only effects of references that contributed additional information to previously published effects were extracted to avoid double counting of effects. Examples of such references are already evaluated VBIDs that are evaluated in a new population or references that contribute a new outcome (e.g., effects on adherence after an extended follow-up).
Correctness of extracted data was revised by a research assistant who compared extracted outcomes and other information with the primary literature. In case of missing information, such as missing standard errors, corresponding authors of primary studies were contacted. Results after matching techniques or after further adjustments were preferred to descriptive results.
Risk of bias
Risk of bias was assessed by the risk of bias tool developed by the Cochrane Review group "Effective Practice and Organization of Care" (EPOC). This tool requires separate assessments of risk of bias in nine risk domains. The tool is recommended for randomized and non-randomized trials and controlled before-after studies [21] . Risk assessment was done on outcome level if possible and on level of reference otherwise. Risk of bias was rated "high" if the evaluation design points to potential problems in respective domains and "low" if those problems could be ruled out. Risk of bias was rated "unsure" if the information given was not sufficient to identify potential problems. Details about decision rules and risk domains are published elsewhere [21] .
Summary effect measure and standard errors
The VBID effect on adherence %-points was used as the summary effect measure. Adherence, the outcome of interest, was defined as the percentage of days with prescribed daily dose availability. For each outcome extracted from primary studies, it was determined to which medicine or indication it related and whether it was assessed up to 1, 2, or 3 years after the VBID index date. For non-randomized studies, effects determined by a DiD framework or an interrupted time series approach were used. If these effects were not given in the primary literature, they were calculated based on the given data. In RCTs, differences in adherence between treatment and control group after VBID implementation without pre-index values were also allowed, because effective randomization usually ensures similar baseline characteristics between groups [27] .
Standard errors of effects were extracted from primary references. If standard errors were not reported, they were calculated with decreasing priority with: (1) 95% confidence intervals; (2) standard deviations and population sizes; (3) p values and population sizes. However, to verify the results, all methods were tested. It was found that methods (1-3) identified very similar standard errors. If exact p values were not given, the level of significance of significant effects was set to be equal to the p value. This is a conservative approach, because it overestimates the p value and large p values imply larger standard errors. Utilized methods for the calculation of standard errors are well-known standard statistical methods [28, 29] . They are, for example, implemented in Review Manager 5.3.
Handling multiple outcomes
Meta-analyses of effects require that effects of distinct and independent study populations are synthesized [30] . To adequately control for correlations between multiple outcomes within the same population and to avoid double counting of effects, populations rather than single references were synthesized. Before entering effects into meta-analyses, correlated outcomes within the same population were combined by a method that considers correlations and is published elsewhere [28] . Because good evidence about correlations between adherence outcomes was not found in the literature and complete dependence or independence was considered to be unlikely, a conservative assumption of a fairly high correlation (r = 0.8) was chosen.
Combination of correlated effects was done for each year after the index year on three levels of aggregation: medication class, indication area, and population level. For example, VBID effects on adherence to all oral antidiabetics are combined to the medication class "oral antidiabetics", and all effects on insulins are combined to the medication class "insulin". The medication classes "insulin" and "oral antidiabetics" are combined to indication area "diabetes". All identified VBID effects were finally aggregated to a population level. Detailed definitions for levels of aggregation are given in Online Appendix C.
Meta-analyses
To estimate time trend-adjusted VBID effects on adherence, three meta-regressions were used. Time trends were estimated as the years elapsed since the VBID index date. A fixed time trend effect was used in all models to adjust the VBID effect. All models used a random, population-specific effect to control for unobserved heterogeneity between populations and to allow multiple outcomes within the same populations [31] . Population-specific effects allow not only the analysis of between-population effects, but also consider within-population effects [32] . Therefore, corresponding analyses provide higher evidence for causality. In the first model, the mean VBID effect was estimated. All VBID effects at the population level were included in this analysis. Because some populations were evaluated at multiple years after the index year, multiple outcomes may exist per population. The same applies to the second (third) model, where VBID effects on the level of different indication areas (medication classes) were estimated accordingly. As before, multiple outcomes per population may occur if evaluations are done after different years or multiple outcomes are reported for different indication areas (medication classes).
In the first model, the time trend effect might be biased by indication area. Because not all references reported VBID effects on medication class level, the third model does not include all populations identified by this review. Therefore, the second model, which used outcomes of all populations, was used to interpret VBID time trend effects.
A meta-analysis on continuous data with generic inverse variance method was used to analyze the association between VBID incentive designs and strength of VBID effects. VBID effects on population level at the end of follow-up were included in this analysis. Associations between incentive designs and effects were analyzed by subgroup analyses of populations with different incentive designs: VBIDs with vs without education, with vs without individualized education, and populations with full vs partial medication coverage.
Because of the heterogeneity of VBID characteristics, incentives, and other confounding, population-specific effects, huge heterogeneity of VBID effects must be expected between patient populations. To account for that heterogeneity, random effect models rather than fixed effect models are chosen. While the fixed effect approach assumes that the between-population variance of effects is zero, the random effects approach controls for that heterogeneity by assuming that the effect estimate varies randomly between populations. Heterogeneity of effects was primarily assessed by between-population variance of effects 2 , which was estimated by the DerSimonian-Laird method [23, 33] . A 5% level of significance was chosen for calculation of standard errors in all analyses.
Sensitivity analyses
To verify the robustness of VBID effects, sensitivity analyses are done. For multiple, correlated outcomes within the same population meta-analyses were rerun with varying assumptions of correlation: perfect independence, medium correlation, and perfect dependence (r = 0, 0.5, 1). In further sensitivity analyses, influence analyses were conducted: first, an outlier was omitted from meta-analyses. Second, all references, including those with high risk of bias, were included.
Publication bias
A contour-enhanced funnel plot was used to interpret small study effects in meta-analysis across all included populations. Compared to usual funnel plots, contour-enhanced funnel plots facilitate the distinction of small study effects that are caused by publication bias from other sources of asymmetry by visualizing areas of statistical significance [23, 34] . Although other causes or pure coincidence could result in small study effects, contour-enhanced funnel plots are commonly used as an indicator of publication bias [34, 35] . Under the assumption that asymmetry of VBID effects was caused by publication bias, trim and fill methods are used to estimate missing studies [34] .
All statistical analyses are done with R 3.4.3. Graphics are done with R 3.4.3, OpenOffice 4.1.5, and Inkscape 0.92.
Results
Selection process
A total of 3798 records were found by database searches (Fig. 1) . Another 35 abstracts were found through other sources. After excluding duplicates, 2419 abstracts were screened. Finally, after applying inclusion criteria, 19 references about 20 populations were included in this review and in sensitivity analyses. Thirteen references with 12 populations were included in primary meta-analyses.
Summary of included studies
An overview of all populations and interventions is given in Table 1 . Two RCTs [15, 36] , including one cluster RCT and one interrupted time series [37] , are identified. All other references include retrospective controlled before-after analyses on claims data [16, 17, [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] . Of retrospective evaluation studies, one natural experiment was identified with reduced copay because of patent expiration [50] . The VBIDs were implemented between 2005 and 2014 in the US. Maximum follow-up ranged between 9 and 36 months. The VBID programs lowered copay in the indication areas heart diseases, asthma, and diabetes. Outcomes are reported on the level of these indications or on the level of medications prescribed for them. Full coverage for at least one tier was offered to 15 populations. In five populations, cost sharing was lowered but not waived. In 16 populations, educational interventions were implemented before or in combination with the VBID. In four populations, VBID alone was compared to usual health care coverage. Individualized educational interventions were implemented in 13 and standardized education in seven populations.
Risk of bias
An overview of results from the risk bias assessment is presented in Online Appendix D. Risk of bias from inappropriate random sequence generation and allocation Redundant subgroups are excluded from all meta-analyses concealment is low in RCTs. Because retrospective controlled before-after studies are not randomized, all other references have a high risk of bias in these domains [21] . In all retrospective studies, baseline differences could be adequately controlled by DiD frameworks, confounderadjusted estimations, and matching techniques. Therefore, risk of bias from dissimilar outcome measurements is low. Risk from dissimilar baseline characteristics is also low in five cases (similar characteristics) and high in 10 references (dissimilar characteristics). In five other references, baseline characteristics are reported, but significance of differences was not analyzed (unclear risk). All RCTs and Clark et al. [39] had complete outcome data or none or only a few participants who were lost to follow-up (low risk of bias from incomplete outcome data). In all other references, the proportion of missing data or the number of participants lost during follow-up was not reported (unclear risk). Generally, risk of bias from knowledge of the allocated intervention can be rated low, because the outcome is objective, since it is based on claims data [21] . In two references, the health plans of enrollees were not known to the investigator. Therefore, unobserved implementation of changes in cost sharing could be possible and risk of contamination bias is high. In other references, risk of contamination bias is low. In the analyses of Reed et al. [49] , treatment and control group changed to a high deductible plan. In the VBID analyzed by Volpp et al. [36] , cost sharing was reduced through payments for prescription fills. In Sedjo, Cox [50] , the analysis is based on a natural experiment of patent expiration. Therefore, the generalizability of findings could be limited and risk from other causes was rated high in these references. In three references on five populations, the control group was constructed from patients who declined program participation [39, 48, 51] . Because of this self-selection, risk of bias from other causes was rated high. References with high risk of bias were excluded from primary meta-analyses, with some exceptions: references with high risk of biases because of non-randomization (domains "random sequence generation" and "allocation concealment") were not excluded because this meta-analysis should not be restricted to RCTs. Aside from that, potential differences in baseline characteristics are controlled by DiD frameworks and were therefore accepted. Because risk of attrition bias could be an issue in almost all references, it was also accepted. Finally, six references with eight populations were excluded from primary meta-analyses.
The VBID effect on adherence
Synthesized VBID effects on adherence at the population level are depicted in Fig. 2 . Significant and positive effects are found in all populations. The unadjusted effect in 12 independent populations was 3.76%-points (p < 0.01). The highest effect was found in "A large employer, 2010", where adherence increased by 14.10%-points. In this population, a VBID with full coverage for generic medications and reduced copay for preferred brands with min/max thresholds for copays and 50% coinsurance for non-preferred medications was evaluated. These monetary incentives were combined with a health and disease coaching program (see Online Appendix E for details on intervention designs).
The time trend-adjusted VBID effect on adherence was 3.18%-points (p < 0.01) ( Table 2 ). In adjusted analyses, K = 19 effects were synthesized. These effects were contributed by all 12 populations, which are included in primary meta-analyses. Of these, five populations contributed multiple outcomes after different lengths of follow-up. This explains the number of synthesized effects. In the meta-regression model 2, on the level of indication areas, VBID effects are significant in each indication (29 effects contributed by all included populations). Highest effects are found for medicines that are indicated in heart diseases (4.05%-points). Each additional year significantly increased this effect by 0.15%-points (p < 0.01). In Mean model 3, the meta-regression on medication class level, the VBID effect on adherence was significant in three of seven medication classes. A total of 31 effects contributed by 10 populations could be included in this model. Highest VBID effects are found on adherence to lipid-lowering medication (4.66%-points, p < 0.01) and to oral antidiabetics (4.60%-points, p < 0.01).
Results from all sensitivity analyses are given in Online Appendix F. In all influential analyses, VBID effects remained significant and time trends were robust. When the outlier was excluded, VBID effects remained most effective in heart diseases, but all effect sizes decreased. VBID effects were robust to inclusion of effects with high risk of bias and to varying assumptions of correlation.
VBID incentive designs
VBIDs that were combined with an existing or new educational intervention were more effective than VBIDs without education (3.95 vs 2.89%points), but the difference was not significant (Table 3) . VBID effects on adherence did not differ between VBIDs with individualized education programs and VBIDs with standardized or no education. A large difference was found between VBIDs that offered full coverage options and VBIDs with only partial coverage. Effects of VBIDs with full coverage were more than twice as high as effects of VBIDs without that option (4.52 vs 1.81%-points, p < 0.05).
Significance of differences between populations with different VBID incentive designs was robust to varying assumptions of correlation (Online Appendix F). In influential analyses, exclusion of the outlier "A large employer, 2010" led to insignificant differences between effects of VBIDs with and without full coverage. However, significant differences between groups remained when all references identified by this review, including high risk of bias effects, were synthesized. In contrast to primary analyses, inclusion of all references was associated with significantly higher effects in VBIDs that were combined with individualized educational interventions compared to VBIDs with standardized or no education (4.57 vs 2.46%-points, p < 0.05). Furthermore, the p value of VBIDs with education effect improved (from p = 0.90 to p = 0.08).
Publication bias
The contour-enhanced funnel plot shows that effects scatter symmetrically around the random effect estimate, which is represented by the dotted line (Fig. 3) . Although all effects were significant, with the trim and fill method, no potentially unpublished effects were estimated into the white area of insignificance. Therefore, no small study effect could be detected. However, as shown in the selection process, three references could not be included because of missing information to calculate standard errors (Fig. 1) .
Discussion
The objective of this systematic review was to identify VBID effects on adherence and incentive designs within these programs that were associated with higher effects. In meta-analyses, 12 distinct populations were included in primary meta-analyses, and up to 20 populations were synthesized in sensitivity analyses.
The VBID effect on adherence
It was found that, across all indication areas, VBIDs significantly increased adherence by 3.18%-points. Stratified to indication areas, VBIDs significantly increased adherence to medications that are indicated in asthma, diabetes, and heart diseases, but effects were highest in heart diseases (4.05%-points, p < 0.0001). High effects in heart diseases were driven by high adherence to lipid-lowering medication. Although these findings were robust to sensitivity analyses, the effect size decreased when the largest outlier was excluded. VBID effects on adherence differed qualitatively by indication and medication class. There are several possible explanations for this observation. First, baseline adherence in some studies differed between medication classes, which might have an impact on achievable effects [39, 47, 51] . Second, side effects are dependent on medication class, and side effects have been shown to be a major driver of adherence [52, 53] .
That VBID effects were highest in heart medication users is unlikely to be explained by low baseline adherence, because across all studies which reported that outcome, baseline adherence to heart medications was highest (diabetes: 46% to 92%, mean 74%; heart diseases: 70% to 91%, mean 79%; asthma: 40% to 52% mean 46%). However, another systematic review on the effect of mobile health interventions on adherence also found higher effects in chronic heart diseases [54] .
Each additional year after VBID implementation increased effects in indication areas by 0.15%-points (p < 0.01). But only evaluation studies up to 3 years could be identified. Therefore, the time trend might not be generalizable to longer periods. Furthermore, because of unclear attrition bias in most studies, non-adherent patients might have dropped out during follow-up. However, the time trend effect was particularly robust in sensitivity analyses with respect to both significance and effect size.
VBID incentive designs
In the present review, it was not possible to quantify the size of monetary incentives because cost-sharing structures of the control group or at baseline were mostly not reported. However, it was found that effects on adherence in VBIDs with full coverage were more than twice as high as in VBIDs without that option. This finding was robust to the inclusion of references with high risk of bias, but not to the exclusion of an outlier [16] . The VBID incentive design of that outlier combines all incentive designs that can be expected to be most effective. Therefore, the extraordinary effects might be driven by incentives and not by unobserved confounders. Although subgroup differences were only able to identify correlations, not causality, this is the first systematic review and meta-analyses that analyzed the significance of differences in VBID effects on adherence between different monetary incentive designs.
In populations where VBIDs were combined with educational interventions, effects on adherence were higher than in populations with other VBIDs, but differences were not significant. Differences between VBIDs with individualized education and other VBID designs could not be shown.
Although, to the knowledge of the author, the VBID effect of education has not been analyzed previously, other studies confirmed the effectiveness of education and similar interventions per se [55, 56] . Furthermore, the number of effects that could be used for subgroup analyses of VBID incentive designs was only 12. Of these, in two populations, VBID alone and, in one population, VBID with standardized education was evaluated. As the number of included populations increased in influential analyses to 20 populations, the p value of the education effect improved and VBIDs with individualized education were significantly more effective. Therefore, this review might simply be underpowered to identify the true education effect. Therefore, further VBID evaluation studies are needed to increase the power to analyze education effects within VBIDs by meta-analyses in detail.
Limitations
There are several potential limitations to discuss. First, unpublished, insignificant, or negative effects of VBIDs could cause publication bias. Furthermore, three references needed to be excluded because standard errors could not be calculated. However, by the trim and fill method, missing populations could not be estimated and, therefore, no small study effects could be identified.
Second, most subgroup meta-analyses had high heterogeneity between-population effects. Heterogeneity might arise from differences between populations in terms of educational background, comorbidities, and other demographic characteristics that are associated with adherence [52] , but also from varying study quality or intervention designs. Therefore, a random effects model that adjusted for between-population variance was chosen. Furthermore, meta-regressions were used to control for unobserved population-specific heterogeneity. However, it could not be ruled out that this heterogeneity caused selection bias in subgroup analyses, especially in unadjusted analyses.
Third, meta-analyses were done on continuous data, which assume normally distributed effects [23] . Because the range of possible effects is actually limited, the assumption of normality was violated. However, VBID effects randomly scattered around the effect estimate, did not exceed 15%-points, and the outlier was analyzed in detail. Therefore, the assumption of approximate normality is considered to be reasonable.
Lastly, the generalizability of synthesized effects is limited because only evaluation periods up to 3 years could be identified, and results are restricted to medications for chronic heart diseases, diabetes, and asthma. Furthermore, only studies from the US were identified, which makes generalization to other countries difficult. Although effects might be smaller in health systems with lower cost sharing, a huge survey of the Commonwealth Fund has shown that individuals in other countries also face financial barriers to adherence and health care [6] .
Given the published evidence, this meta-analysis provides the best evidence available for generalization of VBID effects, as it is the first systematic review and meta-analysis to comprehensively synthesize VBID effects in stratified analyses and to analyze time trends and VBID incentive designs on the basis of high quality research. The findings of this study may provide managerial implications for the implementation of highly effective VBIDs.
Conclusions
Policy-makers can be encouraged to support persistent implementations of VBIDs because these insurance designs have shown to be effective in health insured patients with asthma, diabetes, and especially heart diseases. Furthermore, effectiveness increased with time elapsed since VBID implementation. It was also found that full coverage was associated with higher effects. From a practical perspective this provides valuable guidance on how to make VBIDs more effective. However, further evaluation studies are necessary to thoroughly evaluate the causal effects of specific characteristics of VBID incentive designs and especially of educational interventions alongside VBIDs. The effect of increased cost sharing in VBIDs was not analyzed in this review and may be the subject of further research.
